News coverage about PAREXEL International (NASDAQ:PRXL) has been trending positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. PAREXEL International earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.4179041584069 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of PAREXEL International (PRXL) traded down $0.02 during trading hours on Monday, reaching $88.08. 7,021,100 shares of the company’s stock traded hands, compared to its average volume of 1,041,144. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.45 and a quick ratio of 1.45. PAREXEL International has a one year low of $51.16 and a one year high of $88.10.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/15/parexel-international-prxl-given-news-impact-rating-of-0-28.html.
About PAREXEL International
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Ratings for PAREXEL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International and related companies with MarketBeat.com's FREE daily email newsletter.